Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.63 |
| ▸ | PPARA | Q07869 | 17/20 | 0.63 |
| ▸ | PPARD | Q03181 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017962 | 1.00 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL5761021 | 0.94 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL5025956 | 0.93 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL5025955 | 0.93 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL5016036 | 0.93 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL5016030 | 0.93 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL5017448 | 0.92 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL5759711 | 0.92 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL5759343 | 0.92 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL5017453 | 0.92 | PPARG (0.54) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | claimed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | claimed |
| EP-1392295-B1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | EP | claimed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | claimed |
| US-6969725-B2 | Oxazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-11-29 | — | — | US | claimed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | claimed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | claimed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | claimed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | claimed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | claimed |
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1392295-B1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | disclosed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267180-A1 | Novel oxazole derivatives | NR1H3, NR1H2, PPARD | PPARG 7/4885PPARA 6/4885PPARD 3/4885 |
| US-20030055265-A1 | Oxazole derivatives | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.